

**GREMI Prize 2013 - PhD Thesis Award ex-aequo:
Role of prostaglandin E₂ hydrogen sulfide in the physiopathology of the
human saphenous veins**

Ingrid GOMEZ

**This work was performed under the supervision of Dr Xavier Norel
within INSERM U1148, Paris**

Varicose veins are a form of chronic venous insufficiency, they are characterized by venous backflow and deoxygenated blood stagnation (Jacob *et al.*, 2002). Hypotheses explained that venous hypertension or valves anomalies could be responsible for varicose veins formation (Golledge *et al.*, 2003; Lim *et al.*, 2009). Clinically and histologically varicose saphenous veins reflect a modification of the extracellular matrix and reorganization of the vascular wall (Badier-Commander *et al.*, 2001). Other factors, such as inflammation are still controversial despite the use of anti-inflammatory drugs for pain.

In order to understand the underlying disease mechanism, research has been carried out to study the physiology of healthy and varicose saphenous vein (C2 stage). The major mediators of vascular inflammation such as macrophages, neutrophils, C-reactive protein, pentraxin-3, phospholipase A₂ group IIA (figure 1.) or cyclooxygenase -2, were measured and none of them showed an increased presence or activity in varicose as compared to healthy saphenous veins.




Figure 1. A/ Secreted phospholipase A₂ group IIA (sPLA₂-IIA) mass and enzymatic activity in human small and large diameter varicosities (paired SDv and LDv, n=5) and healthy saphenous veins (SV, n=5). sPLA₂ was determined in the supernatants after 30 min of incubation of venous preparations.

After assessing the role of inflammatory mediators, the role of prostaglandin (PG) E₂ and hydrogen sulfide (H₂S) in this pathology were investigated. PGE₂, a bioactive lipid, can control vascular tone and induces the activation of matrix metalloproteinase (MMPs) (Lee *et al.*, 2011) and is generally increased in inflammation. Recent studies have shown that PGE₂ production can be regulated by H₂S (Li *et al.*, 2013; Whiteman *et al.*, 2010). This endogenous gas could be involved in regulating the cardiovascular system (Liu *et al.*, 2012) and by the inhibition of PGE₂, could act as an anti-inflammatory drugs.

Our experiments have shown that PGE₂ is significantly produced by vascular wall or the perivascular adipose tissue of human healthy saphenous veins (SV). Furthermore, PGE₂ induces a potent vasorelaxation after the activation of its EP4 receptor. The lack of inflammatory involvement confirms that inflammatory activation is not a part of this disease process. PGE₂ and EP4 receptor were decreased in varicose veins, a study their involvement

in vascular wall remodeling was carried out. The reduced synthesis (decreased mPGES-1) and increased degradation (by increased 15-PGDH) of PGE₂ are responsible for its lower concentration in varicose veins. This dysregulation and a lower density of EP4, are responsible for the down-regulation of active MMP-1 and their endogenous inhibitors, TIMP-1 and TIMP-2. In varicose veins, decreased active MMP-1/TIMP-1 and active MMP-1/TIMP-2 calculated from our results, could explain the accumulation of collagen observed in varicose veins. Finally, our experiments have shown that the endogenous H₂S production is two times higher in varicose veins compared to the SV. Using a H₂S donor (NaHS) an inhibition of PGE₂ synthesis has been shown (Figure 2.) and using an inhibitor of the endogenous synthesis of H₂S induces an increased PGE₂ content.




Figure 2. PGE₂ content in human small and large diameter varicosities (paired SDv and LDv, n=16) and healthy saphenous veins (SV, n=15). Controls are presented by red bars. Treatments with NaHS (concentration are expressed in logarithm M, n=9) are presented by white bars. Treatments with H₂S inhibitor (beta cyano L alanine, BCA, concentration are expressed in logarithm M, n=9) are presented by hatched bars. Values are determined by EIA in supernatants after 24h incubation.

In conclusion, H₂S has an anti-inflammatory effect and could be partially responsible for the vascular wall thickening in human varicose saphenous vein. This mechanism could be explain by the inhibition of PGE₂ production as well as by lower ratios of active MMP-1 / TIMP. This endogenous gas could play a protective role in strengthening the vascular wall to resist venous stasis. This vascular wall remodeling could avoid ectasic segment formation and a venous wall rupture.

- Badier-Commander C, Couvelard A, Henin D, Verbeuren T, Michel JB, Jacob MP (2001). Smooth muscle cell modulation and cytokine overproduction in varicose veins. An in situ study. *J Pathol* **193**(3): 398-407.
- Golledge J, Quigley FG (2003). Pathogenesis of varicose veins. *Eur J Vasc Endovasc Surg* **25**(4): 319-324.
- Jacob MP, Cazaubon M, Scemama A, Prie D, Blanchet F, Guillin MC, *et al.* (2002). Plasma matrix metalloproteinase-9 as a marker of blood stasis in varicose veins. *Circulation* **106**(5): 535-538.
- Lee J, Banu SK, Subbarao T, Starzinski-Powitz A, Arosh JA (2011). Selective inhibition of prostaglandin E2 receptors EP2 and EP4 inhibits invasion of human immortalized endometriotic epithelial and stromal cells through suppression of metalloproteinases. *Mol Cell Endocrinol* **332**(1-2): 306-313.
- Li L, Fox B, Keeble J, Salto-Tellez M, Winyard PG, Wood ME, *et al.* (2013). The complex effects of the slow-releasing hydrogen sulfide donor GYY4137 in a model of acute joint inflammation and in human cartilage cells. *J Cell Mol Med* **17**(3): 365-376.
- Lim CS, Davies AH (2009). Pathogenesis of primary varicose veins. *Br J Surg* **96**(11): 1231-1242.
- Liu YH, Lu M, Hu LF, Wong PT, Webb GD, Bian JS (2012). Hydrogen sulfide in the mammalian cardiovascular system. *Antioxid Redox Signal* **17**(1): 141-185.
- Sayer GL, Smith PD (2004). Immunocytochemical characterisation of the inflammatory cell infiltrate of varicose veins. *Eur J Vasc Endovasc Surg* **28**(5): 479-483.
- Whiteman M, Li L, Rose P, Tan CH, Parkinson DB, Moore PK (2010). The effect of hydrogen sulfide donors on lipopolysaccharide-induced formation of inflammatory mediators in macrophages. *Antioxid Redox Signal* **12**(10): 1147-1154.